From: Xenohormone transactivities are inversely associated to serum POPs in Inuit
Male serum | Female serum | ||||||||
---|---|---|---|---|---|---|---|---|---|
Nuuk | Sisimiut | Qaanaaq | All | Nuuk | Sisimiut | Qaanaaq | All | ||
XER RLU/μg protein | n | 32 | 51 | 36 | 119 | 45 | 42 | 32 | 118 |
median | 1.00 | 0.95 | 0.97 | 0.97 | 1.05 | 0.90 | 1.01 | 0.99 | |
mean ± SD | 1.00 ± 0.08 | 0.94 ± 0.08 | 0.98 ± 0.09 | 0.97 ± 0.09 | 1.03 ± 0.08 | 0.94 ± 0.23 | 1.00 ± 0.10 | 0.99 ± 0.16 | |
% agonistic | 6 | 2 | 14 | 7 | 4 | 5 | 6 | 5 | |
% decreased | 9 | 33 | 25 | 24 | 9 | 20 | 28 | 18 | |
P-value* | .09 | .59 | .24 | .07 | |||||
P-value** | .02 (Nuuk and Sisimiut different) | .001 (Sisimiut different) | |||||||
XERcomp RLU/μg protein | n | 32 | 51 | 38 | 121 | 45 | 42 | 32 | 118 |
median | 0.97 | 0.82 | 0.93 | 0.89 | 1.03 | 0.96 | 0.91 | 0.96 | |
mean ± SD | 0.99 ± 0.09 | 0.84 ± 0.09 | 0.91 ± 0.12 | 0.90 ± 0.12 | 1.02 ± 0.11 | 0.95 ± 0.13 | 0.90 ± 0.12 | 0.96 ± 0.13 | |
% further increased | 6 | 2 | 0 | 3 | 34 | 10 | 6 | 14 | |
% antagonistic | 16 | 75 | 37 | 47 | 34 | 0 | 50 | 23 | |
P-value* | .19 | <.001 | .76 | <.001 | |||||
P-value** | <.001 (all different) | <.001 (Nuuk different) | |||||||
XAR RLU/μg protein | n | 34 | 33 | 38 | 110 | 41 | 28 | 33 | 102 |
median | 1.21 | 1.12 | 1.13 | 1.16 | 1.14 | 0.99 | 1.01 | 1.06 | |
mean ± SD | 1.22 ± 0.27 | 1.20 ± 0.29 | 1.16 ± 0.27 | 1.20 ± 0.27 | 1.17 ± 0.29 | 1.01 ± 0.18 | 1.09 ± 0.27 | 1.10 ± 0.26 | |
% agonistic | 18 | 22 | 11 | 17 | 15 | 0 | 12 | 10 | |
% decreased | 6 | 3 | 0 | 3 | 2 | 0 | 0 | 1 | |
P-value* | .50 | .01 | .22 | .01 | |||||
P-value** | .47 (no post hoc test) | .07 (no post hoc test) | |||||||
XARcomp RLU/μg protein | n | 34 | 33 | 38 | 110 | 41 | 28 | 33 | 102 |
median | 1.38 | 1.17 | 0.84 | 1.17 | 0.94 | 0.80 | 0.84 | 0.87 | |
mean ± SD | 1.40 ± 0.27 | 1.24 ± 0.37 | 0.90 ± 0.22 | 1.18 ± 0.36 | 0.99 ± 0.22 | 0.81 ± 0.13 | 0.86 ± 0.21 | 0.90 ± 0.21 | |
% further increased | 50 | 17 | 5 | 23 | 5 | 0 | 6 | 4 | |
% antagonistic | 0 | 6 | 24 | 11 | 12 | 25 | 21 | 19 | |
P-value* | <.001 | <.001 | .49 | <.001 | |||||
P-value** | <.001 (all different) | .001 (Nuuk different) | |||||||
XAR/XER | n | 28 | 33 | 33 | 99 | 41 | 28 | 29 | 98 |
mean ± SD | 1.19 ± 0.27 | 1.29 ± 0.34 | 1.19 ± 0.28 | 1.23 ± 0.30 | 1.14 ± 0.27 | 1.09 ± 0.24 | 1.08 ± 0.25 | 1.11 ± 0.25 | |
P-value* | .51 | .02 | .09 | .004 | |||||
P-value** | .46 (no post hoc test) | .64 (no post hoc test) | |||||||
XARcomp/XERcomp | n | 28 | 33 | 34 | 100 | 41 | 28 | 29 | 98 |
mean ± SD | 1.41 ± 0.29 | 1.50 ± 0.47 | 1.03 ± 0.31 | 1.33 ± 0.43 | 0.98 ± 0.22 | 0.89 ± 0.20 | 0.96 ± 0.26 | 0.95 ± 0.23 | |
P-value* | <.001 | <.001 | .36 | <.001 | |||||
P-value** | <.001 (Qaanaaq different) | .30 (no post hoc test) |